Novartis Ag (NVSEF) Net Income towards Common Stockholders (2009 - 2025)

Novartis Ag has disclosed Net Income towards Common Stockholders across 15 years of filings, most recently posting $4.5 billion for Q2 2025.

• Net Income towards Common Stockholders for Q2 2025 came in at $4.5 billion, up 17.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (down 58.09% YoY), and the FY2025 annual result was $14.0 billion, up 17.11% from the prior year.
• Net Income towards Common Stockholders came in at $4.5 billion for Q2 2025 at Novartis Ag, down from $7.0 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $7.0 billion in Q4 2024 to a low of $46.0 million in Q2 2023.
• The 5-year median for Net Income towards Common Stockholders is $595.0 million (2022), against an average of $2.0 billion.
• Across the five-year window, Net Income towards Common Stockholders sank 97.75% in 2023 and soared 8250.0% in 2024, its largest moves.
• Novartis Ag's Net Income towards Common Stockholders stood at $6.0 billion in 2021, then plunged by 97.46% to $151.0 million in 2022, then gained by 25.83% to $190.0 million in 2023, then soared by 3568.42% to $7.0 billion in 2024, then slumped by 34.99% to $4.5 billion in 2025.
• The last three Net Income towards Common Stockholders figures came in at $4.5 billion (Q2 2025), $7.0 billion (Q4 2024), and $3.8 billion (Q2 2024), per Business Quant data.